- The FDA has granted Orphan Drug Disease Designation to Catalyst Biosciences Inc's CBIO Marzeptacog alfa (activated), or MarzAA, for Factor VII Deficiency (FVIID).
- Factor VII deficiency is a blood clotting disorder that causes excessive or prolonged bleeding after an injury or surgery.
- MarzAA was previously granted Orphan drug and Fast Track Designations for Hemophilia A/B with inhibitors and Fast Track tag for FVIID.
- Related Link: Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA
- Related content: Benzinga's Full FDA Calendar.
- Price Action: CBIO stock closed 2.81% lower at $4.50 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
